CSPC Pharmaceutical (HKEX:1093) accelerated its pipeline with two major moves: a $30M-plus deal with AstraZeneca to co-develop preclinical siRNA renal candidates (potentially worth up to $1.77B) and regulatory clearance to begin Chinese clinical trials for its recombinant shingles vaccine SYS6052.
Previous Week Recap
- CSPC, AstraZeneca Co-Develop Preclinical siRNA Renal: CSPC Pharmaceutical (1093) partners with AstraZeneca to co-develop preclinical siRNA renal candidates; deal includes $30M upfront and up to $1.77B total in potential payments.
- CSPC Receives China Clinical Trial Approval: CSPC Pharmaceutical (1093) got regulatory approval to start clinical trials in China for its recombinant shingles vaccine candidate SYS6052, marking its entry into clinical development.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.